<DOC>
	<DOC>NCT00652847</DOC>
	<brief_summary>To compare the percent (%) change in plasma LDL-C concentration, after a six week course of treatment with ezetimibe 10 mg/day co-administered with an existing statin versus doubling of the existing statin dose</brief_summary>
	<brief_title>Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients With A Diagnosis Of Primary Hypercholesterolemia And Who Are Defined As Being "High Risk" (10Year Risk Of Coronary Artery Disease &gt; 20 % Based On The Framingham Model Or History Of Diabetes Mellitus Or Any Atherosclerosis Disease) And Have Not Reached Their Recommended LdlC Target Levels Of 2.5 Mmol/L While On A Statin Alone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>